{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:10:26Z","timestamp":1777011026997,"version":"3.51.4"},"reference-count":34,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100006108","name":"HHS | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002553"],"award-info":[{"award-number":["UL1TR002553"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201500002C"],"award-info":[{"award-number":["HHSN272201500002C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201300017I"],"award-info":[{"award-number":["HHSN272201300017I"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"HHS | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["K23NS085049"],"award-info":[{"award-number":["K23NS085049"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2021,6,17]]},"abstract":"<jats:p>\n            Botulism is a rare, life-threatening paralytic disease caused by\n            <jats:named-content content-type=\"genus-species\">Clostridium botulinum<\/jats:named-content>\n            neurotoxin (BoNT). Available treatments, including an equine antitoxin and human immune globulin, are given postexposure and challenging to produce and administer.\n          <\/jats:p>","DOI":"10.1128\/aac.02329-20","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T14:42:11Z","timestamp":1618843331000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":18,"title":["Safety, Tolerability, and Pharmacokinetics of NTM-1632, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin B"],"prefix":"10.1128","volume":"65","author":[{"given":"J. T.","family":"Guptill","sequence":"first","affiliation":[{"name":"Department of Neurology, Duke University, Durham, North Carolina, USA"},{"name":"Duke Clinical Research Institute, Durham, North Carolina, USA"},{"name":"Duke Early Phase Clinical Research Unit, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. M.","family":"Raja","sequence":"additional","affiliation":[{"name":"Department of Neurology, Duke University, Durham, North Carolina, USA"},{"name":"Duke Early Phase Clinical Research Unit, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. C.","family":"Juel","sequence":"additional","affiliation":[{"name":"Department of Neurology, Duke University, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. B.","family":"Walter","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA"},{"name":"Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Cohen-Wolkowiez","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina, USA"},{"name":"Duke Early Phase Clinical Research Unit, Durham, North Carolina, USA"},{"name":"Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Hill","sequence":"additional","affiliation":[{"name":"The EMMES Corporation, Rockville, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Sendra","sequence":"additional","affiliation":[{"name":"The EMMES Corporation, Rockville, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Hauser","sequence":"additional","affiliation":[{"name":"Duke Early Phase Clinical Research Unit, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Jackson","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5092-6993","authenticated-orcid":true,"given":"G. K.","family":"Swamy","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA"},{"name":"Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.130.3378.763"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/toxins9060180"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/toxins11120686"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/toxins12010009"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm675152a3"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000370245"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.8.1059"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1409755"},{"key":"e_1_3_2_10_2","volume-title":"Botulism annual summary, 2017.","author":"Centers for Disease Control and Prevention","year":"2019","unstructured":"Centers for Disease Control and Prevention. 2019. Botulism annual summary, 2017. CDC, Atlanta, Georgia."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix814"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix829"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix816"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/DMP.0b013e318158c5fd"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-129-3-199808010-00011"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1504\/TBJ.2015.078132"},{"key":"e_1_3_2_17_2","first-page":"299","article-title":"Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","unstructured":"Centers for Disease Control and Prevention. 2010. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR Morb Mortal Wkly Rep 59:299.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051926"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(80)90469-6"},{"key":"e_1_3_2_20_2","volume-title":"Botulism antitoxin heptavalent (A, B, C, D, E, F, G)\u2013(equine) sterile solution for injection, package insert.","author":"Cangene Corportation","year":"2017","unstructured":"Cangene Corportation. 2017. Botulism antitoxin heptavalent (A, B, C, D, E, F, G)\u2013(equine) sterile solution for injection, package insert. Cangene Corportation, Manitoba, Canada."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02830-14"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01270-19"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.172229899"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.1.570-574.2001"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.3390\/toxins11060345"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.3390\/toxins11040208"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2011.09.030"},{"key":"e_1_3_2_28_2","volume-title":"Investigator's brochure NTM-1632: treatment and prevention of type B botulism posioning, version 1.0.","author":"Nanotherapeutics Incorporated","year":"2016","unstructured":"Nanotherapeutics Incorporated. 2016. Investigator's brochure NTM-1632: treatment and prevention of type B botulism posioning, version 1.0. Nanotherapeutics, Alachua, FL."},{"key":"e_1_3_2_29_2","unstructured":"National Institute of Allergy and Infectious Diseases. 2002. NIAID biodefense research agenda for CDC category A agents. U.S. Department of Health and Human Services Washington D.C. http:\/\/sp.xoma.com\/sites\/RefLib\/Library\/niaid-2002.pdf."},{"key":"e_1_3_2_30_2","volume-title":"Recommendations concerning the select agent program.","author":"Federal Experts Security Advisory Panel","year":"2010","unstructured":"Federal Experts Security Advisory Panel. 2010. Recommendations concerning the select agent program. Department of Health and Human Services, Washington, DC."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1155\/2001\/904148"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03550050095041"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12706"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.3390\/toxins7061854"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197011"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02329-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02329-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:08:28Z","timestamp":1645484908000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02329-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,6,17]]}},"alternative-id":["10.1128\/AAC.02329-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.02329-20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,17]]},"assertion":[{"value":"2020-11-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02329-20"}}